Navigation Links
Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
Date:11/21/2007

microbial resistance. The most advanced compounds include an antibacterial close to NDA-filing and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent, pathogen-focused, late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007. An NDA filing is expected to take place in the second half of 2007.

In June 2007, Arpida announced that it has received approval from the US FDA to initiate Phase II trials with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

An oral formulation of iclaprim has successfully completed three Phase I trials: an ADME study (absorption, distribution, metabolism and excretion) with radiolabelled compound, a Phase I bioavailability trial with a solution and one with a capsule formulation. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An ad
'/>"/>

SOURCE Arpida Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
7. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
9. Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
10. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
11. Blood Donations in U.S. Testing Positive for Chagas Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, ... host a conference call to provide an update ... p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and ... Live web cast: www.neurotropebioscience.com , under "Investor Relations"The ... after completion through September 2, 2014 at (888) ...
(Date:8/20/2014)... Toronto, Canada (PRWEB) August 20, 2014 ... wisdom that E&L studies should be performed late in ... system is known. But current regulatory trends suggest that, ... are on the rise. In recent years, multiple drug ... E&L packages or address specific questions during phase I/II. ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 One ... regenerative medicine is an inadequate vascular supply. Nutrient ... and decellularized tissues is critical for successful regeneration ... attempted to mitigate deficiencies in vascularization and promote ... scaffold bioactivity, optimizing scaffold design and architecture, and ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and ... Fuel Cells (SOFCs) - Global Strategic Business Report" report ... worldwide markets for Solid Oxide Fuel Cells (SOFCs) in US$ ... Canada , Europe , ... estimates and forecasts are provided for the period 2012 through ...
Breaking Biology Technology:Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... Oct. 30 Vical Incorporated,(Nasdaq: VICL ) ... BioFin,Rodman & Renshaw 9th Annual Healthcare Conference will ... Eastern Time. Vical,s President and Chief,Executive Officer, Vijay ... technologies, development programs, and strategic partnerships.,The webcast will ...
... NanoBio(R) Corporation, a,biopharmaceutical company focused on ... and treatment of infectious diseases, today,announced the ... president of,research. Sutcliffe brings 26 years ... of,new antibiotics, with particular emphasis on understanding ...
... Corporation,(Nasdaq: DNDN ) today announced that management will present ... & Renshaw 9th Annual Healthcare Conference The New York ... ET, JMP Securities Healthcare Focus Conference Four Seasons ... ET, Lazard Capital Markets Fourth Annual Healthcare Conference ...
Cached Biology Technology:Vical to Present at Investor Conferences 2Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research 2
(Date:8/21/2014)... of radiations in the 3.3 to 4.4 nanometre range, ... tissues. New theoretical findings show that it is possible ... could be the basis of an optimal technique to ... to be used in high-precision spectroscopy. Now, a new ... generate the harmonic radiationswhich are multiples of an incoming ...
(Date:8/21/2014)... successfully replicated one of the crucial steps in photosynthesis, ... which could manufacture hydrogen as a fuel. , "Water ... exciting prospect to use them to create hydrogen, and ... from the ARC Centre of Excellence for Translational Photosynthesis ... offers potential as a zero-carbon replacement for petroleum products, ...
(Date:8/20/2014)... Huntsman Cancer Institute (HCI) at the University of Utah ... that encodes BCR-ABL, the unregulated enzyme driving the blood ... Cancer Society, nearly 6,000 new cases of CML will ... called tyrosine kinase inhibitors (TKIs), target BCR-ABL and are ... CML but control it in a way that allows ...
Breaking Biology News(10 mins):Water window imaging opportunity 2Water and sunlight the formula for sustainable fuel 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... CAMBRIDGE, Mass. (June 2, 2010) Internationally renowned ... applied worldwide in the biopharmaceutical industry, has achieved ... field of biotechnology. The proven potential for future ... living cells to engineer their surfaces and secreted ...
... the world is fed and fueled will in large ... that is increasingly sustainable or a dead end for ... concludes that dramatically reforming, re-thinking and redesigning two sectorsenergy ... Current patterns of production and consumption of both ...
... climate will increase river runoff to the Baltic Sea, thus ... study from the University of Gothenburg reveals that the effect ... runoff and increase salinity in the Baltic Sea. "There ... researcher Daniel Hansson. The Baltic is a young, brackish ...
Cached Biology News:Chemical biologist and entrepreneur Carolyn Bertozzi awarded $500,000 Lemelson-MIT Prize 2Chemical biologist and entrepreneur Carolyn Bertozzi awarded $500,000 Lemelson-MIT Prize 3Fossil-fuel use and feeding world cause greatest environmental impacts: UNEP panel 2Fossil-fuel use and feeding world cause greatest environmental impacts: UNEP panel 3Fossil-fuel use and feeding world cause greatest environmental impacts: UNEP panel 4Fossil-fuel use and feeding world cause greatest environmental impacts: UNEP panel 5Fossil-fuel use and feeding world cause greatest environmental impacts: UNEP panel 6Warmer climate makes Baltic more salty 2
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
LAB/Probe Mouse-Rabbit DAB Kit...
Mouse monoclonal [SH-A1] to S100 alpha ( Abpromise for all tested applications). entrezGeneID: 6271 SwissProtID: P23297...
G-protein coupled purinergic receptor P2Y8...
Biology Products: